Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Immatics ( (IMTX) ).
On April 17, 2026, Immatics reported that an individual experimental PRAME-directed TCR T-cell therapy, using its IMA203CD8-encoded receptor, induced a deep and durable remission in a 17-year-old with advanced, metastatic nephroblastoma treated at the Hopp Children’s Cancer Center Heidelberg and Heidelberg University Hospital. The patient, who had exhausted all standard options and was ineligible for trials, showed marked regression of lung, liver, brain and abdominal lesions, molecular remission on liquid biopsy and manageable cytokine release syndrome, with the response ongoing at six months and the case selected for a late-breaking clinical poster at the AACR 2026 meeting in San Diego on April 21, 2026.
Immatics said the case underscores PRAME’s potential as a multi-pediatric cancer target, reinforcing the rationale for PRAME-directed cell therapy in children and adolescents with solid tumors. Building on this result and its existing adult solid-tumor programs, the company is now planning pediatric development of its PRAME TCR T-cell therapies, including evaluating options for an initial Phase 1/2 basket trial in HLA-A*02:01-positive, PRAME-expressing relapsed or refractory pediatric solid tumors at the Heidelberg center, a move that could extend its PRAME franchise into high-need pediatric oncology settings and further entrench its leadership in this niche.
The most recent analyst rating on (IMTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
The score is held back primarily by weak and volatile financial performance—especially ongoing cash burn and the sharp 2025 downturn—despite a comparatively strong, low-leverage balance sheet. Technicals are broadly neutral and do not offset the fundamental risk, while valuation support is limited given losses and no dividend.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a Germany-based biotechnology company focused on cancer immunotherapies, positioning itself as a global leader in precision targeting of PRAME, a tumor-associated antigen expressed in more than 50 cancers. The company develops a broad PRAME-focused pipeline spanning TCR T-cell therapies and TCR bispecifics, including lead cell therapy candidate anzu-cel (IMA203), second-generation IMA203CD8 and the bispecific antibody IMA402, targeting solid tumors across multiple indications.
Average Trading Volume: 445,966
Technical Sentiment Signal: Buy
Current Market Cap: $1.47B
For detailed information about IMTX stock, go to TipRanks’ Stock Analysis page.